Literature DB >> 25111315

New regulatory paradigms for innovative drugs to treat pediatric diseases.

Thomas J Hwang1, Florence T Bourgeois2.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25111315      PMCID： PMC4741094          DOI： 10.1001/jamapediatrics.2014.904

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN： 2168-6203            Impact factor:   16.193


× No keyword cloud information.
  6 in total

1.  Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.

Authors:  A S Kesselheim
Journal:  Clin Pharmacol Ther       Date:  2009-06       Impact factor: 6.875

2.  Unintended consequences of regulatory initiatives in childhood cancer drug development.

Authors:  Peter C Adamson
Journal:  JAMA Pediatr       Date:  2013-10       Impact factor: 16.193

3.  "Creating hope" and other incentives for drug development for children.

Authors:  Edward Connor; Pablo Cure
Journal:  Sci Transl Med       Date:  2011-01-19       Impact factor: 17.956

4.  What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.

Authors:  Chandana Thorat; Kui Xu; Scott N Freeman; Renan A Bonnel; Francesca Joseph; M Ian Phillips; Menfo A Imoisili
Journal:  Pediatrics       Date:  2012-02-27       Impact factor: 7.124

5.  Postmarketing trials and pediatric device approvals.

Authors:  Thomas J Hwang; Aaron S Kesselheim; Florence T Bourgeois
Journal:  Pediatrics       Date:  2014-04-14       Impact factor: 7.124

Review 6.  Emergence of pediatric rare diseases: Review of present policies and opportunities for improvement.

Authors:  Supriya Bavisetty; Wayne W Grody; Shahram Yazdani
Journal:  Rare Dis       Date:  2013-01-28
  6 in total
  1 in total

Review 1.  Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges.

Authors:  Antonello Di Paolo; Elena Arrigoni
Journal:  Drugs       Date:  2018-03       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.